Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is … Read more
Trevi Therapeutics Inc (TRVI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.057x
Based on the latest financial reports, Trevi Therapeutics Inc (TRVI) has a cash flow conversion efficiency ratio of -0.057x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.88 Million) by net assets ($189.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Trevi Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Trevi Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Trevi Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Trevi Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genius Sports Ltd
NYSE:GENI
|
0.123x |
|
Befesa SA
XETRA:BFSA
|
0.052x |
|
TRIUMPH FINANCIAL DL-01
F:2THA
|
N/A |
|
PT Gudang Garam Tbk
PINK:GDNGY
|
0.078x |
|
VisEra Technologies Co. Ltd.
TW:6789
|
0.068x |
|
Guangdong Topstar Technology Co Ltd
SHE:300607
|
0.012x |
|
Atul Limited
NSE:ATUL
|
-0.002x |
|
HNA Technology Co Ltd A
SHG:600751
|
0.011x |
Annual Cash Flow Conversion Efficiency for Trevi Therapeutics Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Trevi Therapeutics Inc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $99.64 Million | $-38.26 Million | -0.384x | +0.06% |
| 2023-12-31 | $82.55 Million | $-31.71 Million | -0.384x | -46.51% |
| 2022-12-31 | $107.46 Million | $-28.18 Million | -0.262x | +84.53% |
| 2021-12-31 | $17.07 Million | $-28.95 Million | -1.695x | -59.48% |
| 2020-12-31 | $27.28 Million | $-29.00 Million | -1.063x | -151.07% |
| 2019-12-31 | $54.55 Million | $-23.09 Million | -0.423x | +59.94% |
| 2018-12-31 | $17.31 Million | $-18.29 Million | -1.057x | -95.84% |
| 2017-12-31 | $14.78 Million | $-7.97 Million | -0.540x | -183.95% |
| 2016-12-31 | $-17.41 Million | $-11.19 Million | 0.643x | -- |